Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$38.97 USD

38.97
948,302

+0.43 (1.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.98 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look Out for

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations

Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.

Company News for Jul 8, 2021

Companies in The News Are: BHVN, MSM, SGH, NKLA

New Strong Sell Stocks for June 14th

CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 35.3% Since Last Earnings Report: Can It Continue?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention

The FDA approves Biohaven's (BHVN) Nurtec ODT to prevent migraine besides treating acute migraine attacks.

New Strong Sell Stocks for May 24th

ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021

Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates (Revised)

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -44.178% and 0.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -1.71% and 0.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Q1 Earnings Expected to Decline

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Biohaven (BHVN) Might Surprise This Earnings Season

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).

Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Why Earnings Season Could Be Great for Biohaven (BHVN)

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?

Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.